The Lewis acid catalyzed condensation of 3-methoxyphenol with octanal produced the C(4) symmetric calix[4]resorcinarene 2, in high yield. Of the numerous stereo- and regioisomers possible, the rccc isomer with C(4) symmetry was the only product isolated (as a racemate). The structure has been established by single-crystal X-ray structure analysis.

A water-soluble, chiral calix[4]arene has been found to form hydrogels when triggered by the presence of specific anions, with efficacy linked to the Hofmeister series; the gel properties are modified by the associated cations, and gelation can be reversibly switched off by increasing pH.

Long-term motor complications of dopamine replacement, such as L-DOPA-induced dyskinesia (LID) and reduced quality of L-DOPA action, remain obstacles in the treatment of Parkinson's disease. Dysfunctional glutamatergic neurotransmitter systems have been observed in both the untreated parkinsonian and dyskinetic states and represent novel targets for treatment. Here, we assess the pharmacokinetic profile and corresponding pharmacodynamic effects on behavior of the orally active, selective metabotropic glutamate receptor type 5 (mGlu5) antagonist, 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine (MTEP) (as the hydrochloride salt) in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned macaque. Six parkinsonian, MPTP-lesioned cynomolgus monkeys, with established LID, were administered acute challenges with MTEP (4.5-36 mg/kg p.o.) or vehicle, either alone or in combination with L-DOPA (33 Ϯ 1 mg/kg p.o.). Motor activity, parkinsonian disability, and dyskinesia were assessed for a 6-h period. Plasma drug levels were assessed by liquid chromatography-tandem mass spectrometry. MTEP had no antiparkinsonian action as monotherapy. However, administration of L-DOPA in combination with MTEP (36 mg/kg) reduced peak dose LID by 96%. Moreover, although total on-time (duration for which L-DOPA exerted an antiparkinsonian effect) was not significantly reduced, MTEP (36 mg/kg) reduced the duration of on-time with disabling LID by 70% compared with that for L-DOPA alone. These effects were associated with a peak plasma concentration of 20.9 M and an area under the curve from 0 to 24 h of 136.1 h ⅐ M (36 mg/kg). Although total on-time was not reduced, the peak antiparkinsonian benefit of L-DOPA/MTEP (36 mg/kg) was less than that with L-DOPA alone. Selective mGlu5 inhibitors may have significant potential to ameliorate dyskinesia, but care should be taken to ensure that such effects do not come at the expense of the peak antiparkinsonian benefit of L-DOPA.

Calixarene and resorcinarene macrocycles are renowned for their ability to form inclusion complexes or act as molecular scaffolds. The addition of chirality to these non-planar molecules is an exciting enhancement of their already robust potential, offering much promise as ligands for chiral catalysis and enantioselective separations. Chiral calixarenes can be produced by the attachment of a chiral moiety or by the placement of an achiral functionality on the macrocyclic structure so as to render it asymmetric. The latter method is particularly intriguing, often resulting in molecules which have Cn dissymmetry. This review describes examples of the Cn dissymmetric calixarenes and resorcinarenes prepared to date and discusses aspects of their chirality, including their pictorial and written descriptors.